Immunoglobulin light chain amyloidosis
نویسندگان
چکیده
Summary Immunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal chains. The paraprotein originates from small clonal B‑cell or plasma cell population. If left undetected the can induce number complications based on organ damage. most dangerous dysfunction emerges cardiac involvement. Thus, patients overall survival depends early detection. Establishing correct diagnosis clear characterization amyloid-forming protein, staging, risk assessment treatment are crucial depend highly experienced interdisciplinary, multiprofessional team.
منابع مشابه
Atypical immunoglobulin light chain amyloidosis
BACKGROUND Primary immunoglobulin light chain amyloidosis (AL amyloidosis) is a plasma cell disorder which mainly affects heart, kidneys, liver, and peripheral nervous system. Cases of atypical AL amyloidosis presented as spontaneous vertebral compression fractures have been rarely reported, and data about the management and clinical outcomes of the patients are scarce. METHODS Herein, we pre...
متن کاملHereditary systemic immunoglobulin light-chain amyloidosis.
Several members of a family died from renal failure as a result of systemic amyloidosis. Extensive studies to detect previously documented gene mutations associated with amyloidosis failed to identify a causative factor. In search of the genetic basis for this syndrome, amyloid fibrils were isolated from renal tissue of a member of the kin who died while on renal dialysis. Amino acid sequencing...
متن کاملRisk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.
Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease. This retrospective study examined the frequency of venous thromboembolism in 929 patients with immunoglobulin light chain amyloidosis presenting to a single refer...
متن کاملClinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
BACKGROUND The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described. METHODS Kaplan-Meier and multivariate analyses were performed in a uniformly treated cohort of 145 patients with biopsy-proven AL who were monitored for at l...
متن کاملActivity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myeloma. In the present study, we explored the Pom/dex combination in patients with previously treate...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Memo – Magazine of European Medical Oncology
سال: 2021
ISSN: ['1865-5041', '1865-5076']
DOI: https://doi.org/10.1007/s12254-021-00675-8